Discovery of 1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide analogs as new RORC modulators

Bioorg Med Chem Lett. 2015 May 1;25(9):1892-5. doi: 10.1016/j.bmcl.2015.03.042. Epub 2015 Mar 23.

Abstract

Structure-based and pharmacophore-based virtual screening in combination with combinatorial chemistry and X-ray crystallography led to the discovery of a new class of benzothiadiazole dioxide analogs with functional activity as RORC inverse agonists. The early RORC SAR compound 14 exhibited RORC inhibition in a cell based reporter gene assay of 5.7 μM and bound to RORC with an affinity of 1.6 μM in a fluorescence polarization assay displacing a ligand binding site probe. Crystallography confirmed the binding mode of the compound in the ligand binding domain displaying the engagement of a novel sub pocket close to Ser404. Subsequent optimization yielded compounds with enhanced RORC inverse agonist activity. The most active compound 19 showed an IC50 of 440 nM in a human PBMC assay.

Keywords: Combinatorial chemistry; Crystal structure; Retinoid orphan receptor; Virtual screening.

MeSH terms

  • Benzothiazoles / chemical synthesis
  • Benzothiazoles / chemistry
  • Benzothiazoles / pharmacology*
  • Dose-Response Relationship, Drug
  • Drug Discovery*
  • Humans
  • Molecular Structure
  • Nuclear Receptor Subfamily 1, Group F, Member 3 / agonists*
  • Structure-Activity Relationship

Substances

  • 1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide
  • Benzothiazoles
  • Nuclear Receptor Subfamily 1, Group F, Member 3